Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ATYR vs INMB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Captures Overall Composite Edge (34.3 SELL vs 41.5 SELL), While INMB Leads 3–1 on Growth & Valuation Pillars
ATYR Overall Winner
6-Pillar Tally: ATYR 1 – 3 INMB (2 Tie)
Matrix Metrics: ATYR 1 – 5 INMB
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus INMB at $0.98 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY).
- Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and INMB (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile INMB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ATYR vs INMB
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.96
-5.34% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.67β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
INMB
INmune Bio Inc. Common stock
$0.98
+3.49% 1D
Market Cap
$32.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.64β · 74% Vol
Unified Composite Score
41.5
SELL
Tech 25.0
Fund 50.0
Flow 69.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ATYR 1 – 3 INMB)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
INMB
Revenue Growth (YoY)
+0.0%
+257.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
N/A
Market Cap
$15.6M
$32.5M
3. Profitability & Quality
INMB
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-93.7%
-76.7%
4. Balance Sheet & Cash Flow
INMB
Cash Generation (TTM)
N/A
-$13M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$15M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ATYR
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
154.5% (36th %ile)
326.9% (45th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ATYR (1) vs INMB (5)| Institutional Metric | ATYR | INMB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $15.6M | $32.5M | INMB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +257.1% | INMB | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -93.7% | -76.7% | INMB | |
| 52-Week Range Position | 62% ($0–$8) | 5% ($1–$3) | ATYR | |
| Beta / 30D Volatility | -9.67β · 13806% Vol | 2.64β · 74% Vol | INMB | |
| Unified Institutional Score | 34.3 / 100 (SELL) | 41.5 / 100 (SELL) | INMB | |
| Trailing 12M Revenue (USD) | N/A | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($4.9M Net Cash) | -$13M ($15M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2825.16 pp
3M Horizon
ATYR +887.01 pp
6M Horizon
ATYR +957.46 pp
1Y Horizon
ATYR +589.73 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | INMB Revenue | ATYR Op. Margin | INMB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -5445.0% | N/A | ATYR |
| FY2020 | $10M | $0M | -152.2% | -111163.6% | ATYR |
| FY2021 | N/A | $0M | N/A | -16106.6% | INMB |
| FY2022 | $10M | $0M | -446.8% | -6938.8% | ATYR |
| FY2023 | $0M | $0M | -15557.8% | -19187.7% | ATYR |
| FY2024 | $0M | $0M | -28899.6% | -304535.7% | ATYR |
| FY2025 | $0M | $0M | -40856.3% | -94766.0% | ATYR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
INMB
BREAKDOWN
Current IV
326.9%
IV Percentile
45th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact INMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
INMB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ATYR vs INMB Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus INMB at $0.98 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY). Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and INMB (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile INMB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INMB leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INMB at +257.1% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while INMB shifted N/A. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INMB.
ATYR and INMB trade at balanced relative valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INMB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus INMB (-76.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, INMB carries 326.9% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.64β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
INMB vs ATYR · Reverse Pair
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal